Clovoxamine kinetics in an early clinical trial.

Area of Science:

• Pharmacokinetics
• Clinical Pharmacology
• Neuroscience

Background:

• Understanding drug elimination is crucial for effective antidepressant therapy.
• Preliminary data on clovoxamine's pharmacokinetic profile is needed to guide clinical use.

Purpose of the Study:

• To determine the elimination kinetics of clovoxamine in depressed patients.
• To provide data for optimizing clovoxamine dosage regimens and therapeutic drug monitoring.

Main Methods:

• A preliminary clinical trial involving 10 depressed patients.
• Administration of 50 mg clovoxamine fumarate oral doses.
• Measurement of plasma concentrations to determine pharmacokinetic parameters like half-life (t1/2), volume of distribution (Vd), and oral clearance.

Main Results:

• Mean peak steady-state plasma concentration of clovoxamine was approximately 60 ng/ml at 3 hours.
• Clovoxamine elimination followed first-order kinetics with a mean t1/2 of 9.5 ± 2.8 hours.
• Atypical kinetics were observed in one subject with a significantly longer t1/2 (31.5 hr) and Vd (96 L/kg), impacting plasma concentrations.

Conclusions:

• The determined pharmacokinetic parameters (t1/2, Vd, clearance) are valuable for designing clovoxamine dosage regimens.
• Atypical clovoxamine elimination kinetics can lead to significant variability in plasma concentrations and potentially affect clinical response.